ethyl 2-cyclopentylbenzoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 2-cyclopentylbenzoate
• 英文别名: 6-Cyclopentyl-benzoic acid ethyl ester
• 化学式: C₁₄H₁₈O₂
• 分子量: 218.296
• InChiKey: NXIFETDOSSKENA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ethyl 2-cyclopentylbenzoate 在 水 、 lithium hydroxide 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 5.0h， 以93%的产率得到2-cyclopentylbenzoic acid
  参考文献：
  名称：

  NOVEL COMPOUNDS

  摘要：

  这项发明涉及公式I的化合物，它们作为mGlu5受体活性的正向变构调节剂的用途，含有这些化合物的药物组合物，以及将其用作治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍，如精神分裂症或认知功能下降，如痴呆症或认知障碍的药剂的方法。R1，R2，R3，R4，Q在描述中给出了含义。

  公开号：

  US20130158042A1
• 作为产物：
  描述：

  ethyl 2-(cyclopent-1-en-1-yl)benzoate 在 palladium on activated charcoal 、 氢气 作用下， 以 甲醇 为溶剂， 25.0 ℃ 、103.42 kPa 条件下， 生成 ethyl 2-cyclopentylbenzoate
  参考文献：
  名称：

  MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME

  摘要：

  Described herein, in part, are compounds that mediate the degradation of casein kinase 1α (CK1α), and are therefore useful in the treatment of various disorders, such as cancer.

  公开号：

  WO2023244818A1

文献信息

• [EN] PIPERAZINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLU5 RECEPTORS<br/>[FR] DÉRIVÉS DE PIPÉRAZINE ET LEUR UTILISATION À TITRE DE MODULATEURS ALLOSTÉRIQUES POSITIFS DES RÉCEPTEURS MGLUR5
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2013087805A1

  公开（公告）日：2013-06-20

  This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. R1, R2, R3, R4, Q have meanings given in the description.

  这项发明涉及公式(I)化合物，它们作为mGlu5受体活性的正向变构调节剂的用途，含有这些化合物的药物组合物，以及将其用作治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍，如精神分裂症或认知功能下降，如痴呆症或认知障碍的药剂的方法。R1、R2、R3、R4、Q在描述中有给定的含义。
• NOVEL COMPOUNDS
  申请人：HEIMANN Annekatrin

  公开号：US20130158042A1

  公开（公告）日：2013-06-20

  This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. R 1 , R 2 , R 3 , R 4 , Q have meanings given in the description.

  这项发明涉及公式I的化合物，它们作为mGlu5受体活性的正向变构调节剂的用途，含有这些化合物的药物组合物，以及将其用作治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍，如精神分裂症或认知功能下降，如痴呆症或认知障碍的药剂的方法。R1，R2，R3，R4，Q在描述中给出了含义。
• An Electron-Deficient Diene as Ligand for Palladium-Catalyzed Cross-Coupling Reactions: An Efficient Alkylation of Aryl Iodides by Primary and Secondary Alkylzinc Reagents
  作者：Qiang Liu、Hui Duan、Xiancai Luo、Yang Tang、Gang Li、Rong Huang、Aiwen Lei

  DOI：10.1002/adsc.200800118

  日期：2008.6.9

  An electron-deficient diene, L1, was found to be an effective ligand in facilitating palladium-catalyzed Negishi couplings involving primary and secondary alkylzinc reagents. The reactions took place readily at 60 °C in THF with 5 mol% of a catalyst generated in situ from bis(acetonitrile)palladium dichloride [PdCl2(MeCN)2] and L1, and functional groups such as chloro, bromo, etc. attached to phenyl

  发现缺电子的二烯L 1是促进钯催化的涉及伯烷基锌试剂和仲烷基锌试剂的Negishi偶联的有效配体。反应在60°C的THF中与5 mol％的由双（乙腈）二氯化钯[PdCl 2（MeCN）2 ]和L 1原位生成的催化剂轻松进行，并且对与苯环相连的氯，溴等官能团以及与反应位点相邻的β-H原子具有良好的耐受性。当单独使用异丙基氯化锌作为亲核试剂时，在我们的系统中也观察到了文献报道的反应中涉及的仲烷基锌试剂中存在问题的异构化。然而，当在L 1存在下使用i- Pr 2 Zn时，异构化被显着抑制。
• Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
  申请人：Heimann Annekatrin

  公开号：US08883789B2

  公开（公告）日：2014-11-11

  This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. R1, R2, R3, R4, Q have meanings given in the description.

  本发明涉及公式I的化合物，它们用作mGlu5受体活性的正向变构调节剂，含有它们的制药组合物，以及将它们用作治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍，如精神分裂症或认知衰退，如痴呆或认知损害的药物的方法。 R1，R2，R3，R4，Q在描述中给出其含义。
• Superior Effect of a π-Acceptor Ligand (Phosphine−Electron-Deficient Olefin Ligand) in the Negishi Coupling Involving Alkylzinc Reagents
  作者：Xiancai Luo、Heng Zhang、Hui Duan、Qiang Liu、Lizheng Zhu、Tony Zhang、Aiwen Lei

  DOI：10.1021/ol701995t

  日期：2007.10.1

  [GRAPHICS]Palladium-catalyzed Negishi cross-coupling involving primary and secondary alkyls, even in the presence of beta-H, can be achieved at ambient temperature using chelating ligands containing a phospline and an electron-deficient olefin. The superior effects of the ligands were shown not only in the desired cross-coupling product yields but also in the fast reaction at mild conditions. This reaction has been also scaled up to 50 g in 0.005 mol % catalyst (20,000 TONs) at room temperature.